TCT-588 2-Year Clinical Outcome of the Randomized, Multicenter DUTCH PEERS (TWENTE II) Trial, Comparing Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Stents and Platinum-Chromium Everolimus-Eluting Promus Element Stents in “All-Comer” Patients

Clemens von Birgelen, Ming Kai Lam, Liefke C. van der Heijden, Peter W. Danse, Gillian A.J. Jessurun, R. Melvyn Tjon Joe Gin, Rutger Anthonio, Gert K. van Houwelingen, Frits H.A.F. de Man, Martin G. Stoel, Hans W. Louwerenburg, Gerard C.M. Linssen, Marc Hartmann, Marije M. Löwik, Kenneth Tandjung, Maarten Joost IJzerman, Carine J.M. Doggen, Hanim Sen

Research output: Contribution to journalMeeting AbstractOther research output

38 Downloads (Pure)

Abstract

Background: The multicenter, prospective, randomized, single-blinded, investigator-initiated DUTCH PEERS (TWENTE II) “All Comers” Trial demonstrated at 1-year follow-up the non-inferiority of third-generation Resolute Integrity zotarolimus-eluting stents (Medtronic Vascular, Santa Rosa, CA) versus Promus Element everolimus-eluting stents (Boston Scientific, Natick, MA), based on a similar incidence of the primary endpoint target vessel failure (TVF), a composite of cardiac death, target vessel revascularization (TVR), or myocardial infarction (MI). No other follow-up data beyond 12 months have been published from a randomized head-to-head comparison of both stents.

Methods: In 4 study centers in the Netherlands, 1,811 patients were 1:1 randomly assigned to treatment with one of both stents. Patients with any clinical syndrome, any lesion type, and any number of lesions or vessels to be treated were included. Study monitoring and clinical event adjudication were performed by two independent Dutch contract research organizations (Diagram, Zwolle, and Cardialysis, Rotterdam, respectively).

Results: DUTCH PEERS examines an all-comer patient population that included 59% of patients with acute coronary syndromes (20% of all patients presented with an acute STEMI) and 66% of patients with complex target lesions. We will compare for both stent groups the 2-year incidence of TVF (primary endpoint) and various secondary endpoints, including individual components of the primary endpoint, the incidence of stent thrombosis, and other composite endpoints, such as target lesion failure, major adverse cardiac events, and the patient-oriented composite endpoint. In addition, we will report the outcome of patients with longitudinal stent deformation after discontinuation of dual anti-platelet therapy.

Conclusions: Clinical outcome of the DUTCH PEERS trial at 2-year follow-up will be presented.
Original languageEnglish
Pages (from-to)B171-B171
JournalJournal of the American College of Cardiology
Volume64
Issue number11, suppl.
DOIs
Publication statusPublished - 2014

Keywords

  • METIS-310839
  • IR-96253

Fingerprint Dive into the research topics of 'TCT-588 2-Year Clinical Outcome of the Randomized, Multicenter DUTCH PEERS (TWENTE II) Trial, Comparing Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Stents and Platinum-Chromium Everolimus-Eluting Promus Element Stents in “All-Comer” Patients'. Together they form a unique fingerprint.

  • Cite this